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Context:In Prader-Willi Syndrome (PWS), an altered GH secretion has been related to reduced
cardiac mass and systolic function compared to controls.
Objectives: To evaluate the cardiovascular response to a 4 yr GH therapy in adult PWS patients.
Study participants: Nine severely obese PWS adults (3 females, 6 males) and 13 age-, gender- and
BMI-matched obese controls.
Methods: In an open-label prospective study, assessment of endocrine parameters and metabolic
outcome, whole body and abdominal fat scans, echocardiography, radionuclide angiography in
unstimulated and dobutamine-stimulated conditions were conducted at baseline and after 1 and
4 yr of GH treatment.
Results: GH treatment increased IGF-I (P0.0001), decreased C-reactive protein levels (P0.05),
improvedvisceral fatmass (P0.05), andachievednear-significant changesof fat and fat-freebody
mass in PWS patients. Left ventricle mass indexed by fat mass increased significantly after 1 yr and
4 yr of GH therapy (P0.05) without evident abnormalities of diastolic function, while a trend
toward a reduction of the ejection fraction was documented by echocardiography (P0.054).
Radionuclide angiography revealed stable values throughout the study both of the left and right
ventricle ejection fraction, though being accompanied by a statistically not significant reduction
of the left ventricle filling rate. A positive association between lean body mass and LVEF was
evident during the study (P 0.05).
Conclusions:GHtherapy increased cardiacmass of PWSadultswithout causingovert abnormalities
of systolic and diastolic function. While the association between lean mass and left ventricle ejec-
tion fraction during GH therapy corroborates a favorable systemic outcome of long-term GH
treatment in adults with Prader-Willi syndrome, subtle longitudinal modifications of functional
parameters advocate appropriate cardiac monitoring in the long-term therapeutic strategy for
Prader-Willi Syndrome.
Prader-Willi Syndrome (PWS) is a rare monogenic dis-order associated with neuro-cognitive, musculoskel-
etal and obesity-related disorders, which contribute to en-
hanced propensity to cardio-respiratory and metabolic
complications (1–3). Patients with PWS are considered to
be growth hormone (GH)-deficient, although study find-
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ings differ largely on the prevalence of this clinical feature
in the adult population (4, 5). Overall, GH deficiency
(GHD) is believed to influence the adult PWS phenotype,
being associated with short stature, increased adiposity
and decreased lean mass as opposed to essential obesity,
where both lean bodymass and fat mass are increased (6).
GHD is a defined clinical syndrome associated with an
unfavourable cardiovascular profile, which improves
with GH therapy (7). The therapeutic rationale for using
GH to treat patients with PWS stems both from the dem-
onstration of quantitatively and qualitatively abnormal
dynamics of GH secretion (8), and from observed clinical
similarities between individuals with GHD without PWS
andPWSpatients,who are commonly foundwith reduced
muscle strength, altered body composition, low energy
expenditure, and reduced statural growth, even in the
presence of obesity (9). Within the endocrine care com-
munity, increasing experience has accumulated over the
past few years on the ability of GH treatment to alleviate
some dysfunctions of PWSpatients. In childrenwith PWS,
GH treatment normalizes stature and ameliorates body
composition, fat utilization, and muscle strength (10).
These effects are maintained during a 8 years GH treat-
ment (11), and tend to perdure upon treatment discontin-
uation (12). To date, there are no controlled studies of
uninterrupted GH treatment through childhood, adoles-
cence, and the transitional period into adulthood in PWS.
Despite a shorter clinical experience, there is a strong like-
lihoodof a sustained benefit exerted byGH treatment also
in PWS adults (9), where GH treatment can favorably
decrease adiposity (13,14) and improvemusclebulk,mus-
cle power, and exercise tolerance (15). These changes are
expected to favor the control of body mass in PWS. Op-
positely, there is evidence that cessationofGHtherapy can
worsen BMI, thus that long-term use of GH may be ad-
visable to maintain good body composition and prevent
complications of obesity in adult PWS patients (16).
To date, only a limited number of studies investigated
the cardiovascular featuresofPWSpatients indetail. Phys-
ical examination, ECGrecordings and transthoracic echo-
cardiograms including two-dimensional speckle-tracking
echocardiography have been used to assess cardiac anat-
omy and myocardial systolic function in children with
PWS, and found frequent alterations in myocardial sys-
tolic function, while conventional echocardiographic
findings failed to uncover ventricular systolic dysfunction
(17). In a group of adult PWS patients, key evidence of
significantly raised levels of the inflammatory marker hs-
CRP, microcirculatory dysfunction and occasional sinus
node dysfunction, all of which are associated with early
sudden death, were documented (18). In addition, obese
PWS adults have been found to harbor hypokinetic car-
diac features resembling those of GHD, ie, lower systolic
function, smaller left ventricle (LV) size and impaired
chronotropic response to an adrenergic stimulus (19).
Some of these features can improvewithGH therapy (20),
yet the chronic effects of GH administration on the car-
diovascular system in the setting of PWS are completely
unknown.
The current study aimed to explore if long-term GH
therapy modifies the clinical outcome in PWS adults by
evaluating its efficacy on metabolic homeostasis, adipos-
ity indices, and structural and functional cardiovascular
features in obese PWS adults.
Patients and Methods
Study design.Data presented in the current study are based on a
4-year prospective study of 9 PWS adult subjects who took orig-
inally part to a 12-month trial performed on 13 patients and
previously published (20). Of the initial group of 13 patients, 4
patients withdrew GH treatment within two years after starting
therapy and refused to undergo the final cardiovascular testing
after 4 years. Reasons for withdrawing GH were excessive gain
of body mass due to insufficient familiar control (n 2), lack of
motivation (n 1) and inadequate compliance to GH adminis-
tration (n 1). As such, current analysis refers exclusively to the
9 patients (3 females, 6 males; age 26.4  3.7 years) who com-
pleted the whole study and includes results obtained at study
entry, after 1 year and 4 yearsGH treatment.Of these, 2 patients
underwent the radionuclide study only in unstimulated condi-
tions, due to potential pharmacological interference with the
dobutamine stimulus. As controls, 13 age-, sex-, and BMI-
matched otherwise healthy individuals (6 females, 7 males; age
26.2  3.1 year) were selected from the hospital patients and
accepted to partake into the study. All patients and their obese
control subjects were studied as in-patients, after two resting
days and overnight fasting. The experimental procedure was
approved by the ad hoc Ethical Research Committee of the Is-
tituto Auxologico Italiano, Verbania, Italy. Written informed
consentwas obtained from the PWSpatients and their parents or
guardians, and from the obese participants. The study protocol
conformed to the guidelines of the Additional Protocol to the
European Convention on Human Rights and Biomedicine, con-
cerning Biomedical Research.
Subjects. All subjects included in the study were Caucasian and
aged over 18 years. All PWS patients exhibited the typical phe-
notype (2), suffered from childhood obesity and were undergo-
ing strict parental guidance to achieve control of their feeding
obsession. Cytogenetic analysis was performed in all subjects,
and 7 carried the deletion of the paternal chromosome 15
(15q11-q13), whilematernal uniparental disomywas diagnosed
in the remaining 2. No study participant or their families re-
ported on any previous heart problems. At baseline, all partici-
pants reported a stable body mass for the previous 3 months,
none suffered from impaired thyroid, adrenal, renal or hepatic
function nor had been previously subjected to any pharmaco-
logical or surgical treatment for loss of body mass. Four PWS
patients had previously undergone GH treatment, withdrawn in
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all cases 1–4 years before enrolment in the current study. Pitu-
itaryGHsecretionwas evaluated inPWSbydynamic testingwith
GHRH  arginine. The threshold of peak GH levels used for
diagnosis of GHD was 4.1 g/liter (21). Four out of 9 PWS
patients satisfied the criterionofGHD. Since the original visit, all
PWS patients had been regularly attending the hospital and sub-
jected to EKG and cardiology consultation yearly to assess any
variation that would advocate for therapy withdrawal while on
GH treatment. At baseline, 2 patients suffering from arterial
hypertension were receiving therapy with loop diuretics (n 1)
and angiotensin-converting enzyme (ACE) inhibitor plus cal-
cium antagonist (n 1). One hypertensive patient also suffered
from type 2 diabetes mellitus and was insulin treated. All PWS
were reported to have behavioral problems, and 4 subjects were
treated with neuroleptics. All therapies did not vary both at 1
year and 4 years time-points, with the exception of 1 male who
stopped neuroleptic therapy after 1 year of GH administration.
One of two PWS women with primary amenorrhea was under-
going sex steroid substitutive therapy, and the remaining suf-
fered from oligomenorrhea. There had been no changes in the
replacement dose of hormones other than GH since the original
trial. GH treatment was administered at bedtime, with a mean
GH dose of 0.97  17 mg/d after the first 12-month period.
Subsequently, the dose was adjusted to maintain serum total
IGF-1 levels within 2 SD from an age-matched reference value,
so as to avoid overdosing. The final dose attained after 48
months in the PWS patients group was 0.40  0.11 mg/d. Ar-
thralgia and fluid retention were the only documented side-ef-
fects andwere limited to the first month of treatment in 1 female
patient. GH therapy was self-injected by one patient and admin-
istered by patient’s parents or their caregiver in the remainders.
Anthropometric measures. Determination of stature and body
masswere obtained in fasting conditions, after voiding. BMIwas
defined as body mass in kilograms divided by the square of stat-
ure in centimeters. Waist was measured as halfway between the
costal edge and the crista. Hip was measured as the greatest
circumference around the nates. Dual-energy x-ray absorptiom-
etry (DXA) was used for assessment of body mass (GE-Lunar,
Madison, WI), expressed as lean body fat in kilograms and fat
bodymass as percentage of total bodymass. Abdominal visceral
adipose tissue (VAT) and subcutaneous adipose tissue (SAT)
were measured by 6-mm single-slice L4-level computed tomog-
raphy (CT) using GE Hi-Speed DX/I with 6.4 CT scanner soft-
ware (General ElectricMedical Systems,Milwaukee,WI). Intra-
abdominal fatwas separated fromretroperitoneal fatbydrawing
a line to the pericolic gutters. Sagittal diameter was measured as
the anterior-to-posterior distance inmillimeters at the disk level.
A single image was obtained during suspended respiration. The
within-subject variation for repeated analyses of fat measure-
ment in our laboratory is1%.Arterial bloodpressure (BP)was
recorded in the sitting position after at least 30 minutes of rest.
At least two measurements were taken, and the mean value was
recorded.
Cardiac analyses. Assessment procedures have been previously
described (19) and will be briefly summarized. Echocardiogra-
phy was performed by M-mode, two-dimensional, and pulsed
Doppler studies (Hewlett-Packard Sonos 2500, Andover, MA)
by one echocardiographer throughout the course of GH treat-
ment. The following measurements were recorded on M-mode
tracing: interventricular septum thickness (IVST; millimeters),
left ventricular (LV) posterior wall thickness (LVPWT, millime-
ters), LV end-diastole diameter (LVEDD, millimeters), LV end-
diastole volume (LVEDV,millilitres); calculation of the LVmass
(LVM, grams) was made using the Devereux’s formula accord-
ing to the Penn convention with the following regression-cor-
rected cube formula: LVM  1.04 [(IVST  LVEDD 
LVPWT)3) - (LVEDD)3] - 14 g, and calculated after correction
for body surface area (BSA) (LVMBSA, grams per square meter),
height2.7 (LVMh2.7), or percent fat mass (LVMFM, grams, per-
cent). Doppler studies provided indices of ventricular filling that
were derived from the mitral flow velocities curves, ie, maximal
early diastolic flowvelocity (E, centimetres per second),maximal
late diastolic flow velocity (A, centimetres per second), peak E/A
wave velocity ratio (normal value 1 or more), and the decelera-
tion time of early filling (DT, milliseconds). Equilibrium radio-
nuclide ventriculography was performed at rest and during do-
butamine infusion. Acquisitions were obtained with patients in
supine position in the left anterior oblique best septal view with
a large field-of-view camera (Apex 409, Elcsint, Haifa, Israel)
equipped with a parallel-hole high-sensitivity collimator. Data
were collected in minilist mode to compensate for heart vari-
ability during acquisition. Dobutamine infusion was performed
in 5-minute steps; image acquisitionwas obtained during the last
3minutes of each step. LV ejection fraction (LVEF, percent) was
computed on the basis of relative end-diastolic and end-systolic
counts. In all participants, framing rate was sufficiently high to
allow calculation of diastolic parameters. Accordingly, peak fill-
ing rate (PFR) was computed from the first derivative of a third-
order polynomial function fitted to the first two thirds of the
diastolic portion of the LV time-activity curve by a least squares
technique, normalized for end-diastolic volume (EDV) and ex-
pressed asEDVper second.As normal, the following valueswere
taken in consideration: LVEF 50% or more in basal conditions
with 5% increments or more during dobutamine, and PFR 2.5
EDV/sec or more.
Hormoneassays.Measurementswere performedusing commer-
cially available kits. All samples were analyzed separately at
baseline and at the 1 year and 4 years points. GH levels were
measured by chemiluminescence (Immulite 2000 analyzer, Di-
agnostic ProductsCorp., LosAngeles,CA)having a sensitivity of
0.01 g/liter and intra- and interassay coefficients of variation
(CVs) of 2.9–4.2 and 4.2–6.5%, respectively. Total IGF-I levels
were assayed by chemiluminescence IGF-I immunoassay by Li-
aison (Nichols Advantage, San Juan Capistrano, CA), having a
sensitivity of 6g/liter, intraassay and interassay CVs of 4.8 and
6.7%, respectively. Serum insulin levels were measured by
chemiluminescence (Immulite 2000). Enzymatic methods
(Roche Molecular Biochemicals, Mannheim, Germany) were
used for determination of blood glucose, total cholesterol, high-
density lipoprotein (HDL)-cholesterol, low-density lipoprotein
(LDL)-cholesterol and triglycerides. Insulin resistance was mea-
suredbyhomeostaticmodel approach [HOMA, insulin (U/mL)
* blood glucose (mmol/L)/22.5]. Ultrasensitive C-reactive pro-
tein (CRP) was measured by HS Roche kit.
Data analysis Results are presented as meanSEM.Two-tailed
Mann-Whitney and paired Student’s t test were used for com-
parison between PWSand control group, and in PWSduringGH
therapy, respectively.Analysis of variationswasused to calculate
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differences between baseline, 1 year and 4 years time-points.
Relationships between variables were analyzed using Pearson’s
correlation analysis after merging datasets from the three time-
points, to make the analysis numerically more consistent. Anal-
yses were performed using SPSS 18.0 (SPSS, Inc., Chicago, IL).
Significance was accepted for P  .05.
Results
Hormone and body composition investigations.No PWS
patientwhocompleted the studycomplainedof significant
side effects nor developed adverse events during the period
of GH treatment, and none withdrew therapy. Compared
to obese controls, PWS patients showed significantly
lower IGF-I levels which steadily increased at the 1- and
4-year follow-up during GH treatment (P  .0001 vs.
baseline for both) and proportionately to the GH treat-
ment dose (Table 1). Indirect adipositymeasures, ie, waist
and waist-to-hip ratio, were similar between PWS and
controls, and were unchanged by the end of the study.
Inversely, DXA measured a markedly different accumu-
lation in fat and fat-free body mass between PWS and
controls. At the end of the treatment period, a near-sig-
nificant increase of lean body mass occurred in the PWS
group (3kg;P .053vs. baseline),whichwasassociated
to a slight reduction of the percent body fat at this time-
point (P  .08). By abdominal CT scan, we found no
difference in SAT or VAT accumulation between groups,
while a marked reduction of VAT was seen at the 1 year
and 4 years follow-up in all but one PWS male patient
(cumulative variation vs. baseline: –30.1% and –30.3%;
P  .007 and P  .01, respectively). GH therapy elicited
variable reductions of SAT compartment (-8.9% vs. base-
line), albeit unexpectedly increasing in one male and one
female patient (4% and 28% by the end of the study).
At baseline, we found no difference between PWS and
controls in glucose levels, while insulin concentrations
were significantly lower in the former group (Table 1).GH
therapywas associatedwith a transient increase in glucose
levels at the 1 year visit (P .006), then returning to values
not dissimilar from baseline concentrations at the 4 years
visit. Insulin levels increased in three PWS patients during
therapy and remained stable in the remaining ones by the
study end. HOMA-IR values showed a trend toward an
increase at the 1 year and 4 years follow-up and were,
cumulatively, subordinated to measures of adiposity
(BMI: r  0.70, P  .0001; percent fat body mass: r 
0.41, P .05). However, final indices of glucose homeo-
stasis were not different from those measured in controls
(Table 1). CRP levels decreased significantly in PWS
treated with GH after 1 (P .001) and 4 years (P .03).
All parameters of lipid homeostasis except for HDL-cho-
lesterol were (nonsignificantly) healthier in PWS subjects
Table 1. anthropometric and biochemical results (meanSEM) obtained in 9 PWS patients at baseline and after 1
and 4 yr of GH treatment. Comparative data from 13 obese control subjects are included.
Parameters Control subjects (n  13)
PWS patients
(n  9)
GH treatment P value
baseline 1 yr 4 yr (ANOVA)
Body mass (kg) 125.4  3.6 108.7  3.6b 110.4  5.7a 110.4  6.4a 0.9
Body mass index (kg/m2) 43.0  1.4 44.9  1.6 45.5  2.4 45.5  2.5 0.9
Waist/hip 0.91  0.02 0.94  0.02 0.93  0.02 0.94  0.01 0.9
IGF-I (g/liter) 155.3  13.8 86.0  9.6b 347.7  36.2bd 197.9  18.9bd 0.0001
Plasma glucose (mg/dl) 85.7  3.1 85.1  8.5 95.2  7.9d 89.4  10.1 0.7
Insulin (mUI/ml) 15.6  2.0 9.5  1.6a 15.8  4.4 14.4  3.5 0.4
HOMA-IR 3.3  0.5 2.0  0.4 3.8  1.1 3.0  0.7 0.3
C-reactive protein (mg/dl) 0.97  0.22 0.98  0.16 0.43  0.13c 0.57  0.16d 0.04
Triglycerides (mg/dl) 172.4  27.8 115.4  15.4 116.1  13.9 98.6  8.8 0.6
Total-cholesterol (mg/dl) 215.5  13.3 177.1  15.0 184.7  14.0 178.0  12.7 0.9
LDL-cholesterol (mg/dl) 148.2  10.7 118.8  12.3 124.9  13.0 114.3  14.0 0.8
HDL-cholesterol (mg/dl) 45.6  2.6 45.3  4.1 69.7  3.0 55.2  7.9 0.4
Fat mass (%)† 46.3  1.8 55.5  1.8b 53.1  1.9a 52.9  1.4a 0.4
Fat-free mass (kg)† 60.5  3.7 47.7  2.4a 49.8  2.3a 50.7  2.5a 0.6
SAT (cm2)‡ 675.5  33.6 693.8  36.2 635.1  37.1 622.6  42.7 0.4
VAT (cm2)‡ 150.1  24.8 158.1  23.9 110.6  19.5d 111.5  18.3c 0.2
APD (cm)‡ 30.1  6 29.9  1.0 29.6  1.42 30.3  1.2 0.9
For significance: differences between controls and PWS are indicated as a (P  0.05), b (P  0.01); differences within the PWS group between
1 yr and 4 yr GH treatment and vs. baseline are indicated by ANOVA and as d (P  0.05), e (P  0.01).
Abbreviations: HOMA-IR and -IS, homeostatic model approach insulin resistance and sensitivity; SAT and VAT, abdominal subcutaneous and
visceral adipose tissue; APD, abdominal antero-posterior diameter.
†, as determined by total-body DXA
‡, as determined by abdominal CT scans
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than obese controls. Despite the lack of significant mod-
ifications of lipid levels during the course of GH therapy,
HDL-cholesterol levels increased by 22%by the study end
in PWS. Neither the GH dose at each time point nor the
attained IGF-I levels were associated to any metabolic
variables obtained during the study period.
Cardiovascular exams.Diastolic and systolic BPwere sta-
ble during the course of GH treatment (Table 2). Echo-
cardiography showed no hypertrophic effect ofGHon the
interventricular septum and posterior wall of the LV.
However, an increase in LV end-diastole diameter oc-
curred after 1 year and 4 years, which was reflected in the
increase of LVmassFM after 1 year (delta, 11.9%; P .02
vs. baseline) and 4 years ofGH therapy (delta, 11.6%;P
.07 vs. baseline). Correlation analysis on cumulative lon-
gitudinal data displayed a direct association between the
LV massFM and lean body mass (r  0.62, P  .001)
achieved during the treatment period (Figure 1). Doppler
analysis revealed a normal systolic function (eg, LV EF
55%) in all PWS subjects throughout the study, and final
values did not differ from those of controls, despite a re-
duction of LV EF at 1 year and 4 years visit (P .03 and
P  .02, respectively). Diastolic function was preserved
(eg, E/A ratio 1) in all PWS patients duringGH therapy,
and individual values of the E/A ratio were inversely re-
lated to BMI (r-0.64, P  .0001; Figure 2) and
HOMA-IR (r-0.55, P .003). A decline of the deceler-
ation timewas seen after 1 year and4years of therapy (P
.02 and P  .04, respectively).
Radionuclide angiography analysis was obtained
throughout the study in unstimulated conditions (ie, base-
line) and after -adrenergic stimulus, and documented an
overall broad stability of LV systolic and diastolic activ-
ities during theGHtreatment course inPWS.Left ventricle
EFdidnot change significantlyduring treatment (Table2),
and correlated positively to the lean body mass (Figure 3)
Table 2. echocardiography and radionuclide angiography results (mean[plusmn]SEM) obtained in PWS patients at
baseline and after 1 and 4 yr of GH treatment. Comparative data from obese control subjects are included.






baseline 1 yr 4 yr (ANOVA)
Echocardiography
LVPWT (mm) 10.1  0.3 9.2  0.4 8.9  0.2 9.0  0.4 0.8
IVST (mm) 9.5  0.3 9.6  0.3 9.1  0.4 9.7  0.4 0.7
LVM (g) 163.5  7.6 133.7  6.7a 146.6  5.5 150.1  9.0 0.3
LVMBSA (g/m
2) 70.6  2.9 64.6  3.0 71.2  1.7 72.8  3.9 0.2
LVMh (g/h
2.7) 39.5  1.9 40.3  1.6 44.5  1.8 45.5  2.8 0.3
LVMFM (g%) 3.7  0.3 2.4  0.1
b 2.8  0.1ac 2.8  0.1a 0.2
LVEDD (mm) 47.0  1.1 43.0  1.4 47.1  1.2c 46.2  1.2 0.1
LVEDV (mL) 46.3  1.6 47.1  3.2 49.7  2.8 50.6  2.9 0.8
LVEF (%) 60.6  1.5 64.0  1.5 59.0  1.7c 60.0  1.5c 0.2
E/A 1.6  0.1 1.6  0.1 1.7  0.1 1.5  0.1 0.7
DT (msec) 175.4  4.1 192.1  7.2 170.6  4.2c 168.9  2.8c 0.02
Radionuclide angiography
LVEFBAS (%) 58.6  1.5 55.7  1.7 54.8  2.0 54.9  1.5 0.9
LVEFDOB (%) 76.4  1.1 72.1  2.2 69.3  1.7
d 67.9  1.4d 0.4
 LVEF (%) 31.3  3.1 30.3  2.7 30.9  6.7 26.4  1.4 0.8
RVEFBAS (%) 44.9  1.7 42.5  2.2 39.4  1.2
c 43.7  2.0 0.4
RVEFDOB (%) 61.7  1.4 55.7  1.8 62.1  1.8 57.0  3.6 0.4
 RVEF (%) 42.6  3.5 35.3  8.1 58.0  4.2a 30.1  2.9c 0.04
PFRBAS (EDV/s) 2.9  0.2 2.6  0.2 2.6  0.2 2.5  0.1 0.8
PFRDOB (EDV/s) 4.5  0.3 4.1  0.3 3.4  0.2
a 3.6  0.3a 0.4
 PFR (%) 56.2  7.2 67.4  14.1 48.3  20.6 57.5  11.6 0.8
HRBAS (bpm) 68.3  2.7 62.9  3.8 63.9  2.9 62.6  3.6 0.9
HRDOB (bpm) 128.7  2.5 107.4  7.7
a 108.6  6.7a 116.3  4.5a 0.7
 HR (%) 92.9  8.9 60.9  10.4 67.9  8.1 81.8  6.5 0.4
DBPBAS (mmHg) 78.5  1.8 77.5  1.2 76.3  1.4 77.9  1.9 0.8
DBPDOB (mmHg) 83.1  2.8 78.6  1.9 78.6  1.9 78.8  4.1 0.9
SBPBAS (mmHg) 125.8  3.6 120.0  2.3 122.5  3.0 121.4  6.5 0.9
SBPDOB (mmHg) 145.4  8.2 141.4  6.7 133.6  4.1 132.9  3.1 0.7
For significance: a (P  0.05) and b (P  0.01), obese controls vs. PWS patients; c (P  0.05) and d (P  0.01), 1-yr and 4-yr GH treatment vs.
baseline in PWS patients.
Abbreviations: LV and RV, left and right ventricles; PWT, posterior wall thickness; IVT, interventricular septum thickness; LVM, left ventricle
mass; LVMi, LVM indexed by body surface area; LVMh, LVM indexed by height
2.7; LVMFM, LVM indexed by percent fat mass; LVEDD, LV end-
diastole diameter; LVEF, LV ejection fraction; E/A, early-to-late mitral peak flow velocity; DT, deceleration time; RVEF, right ventricle ejection
fraction; PFR, peak filling rate; HR, heart rate; DBP and SBP, diastolic and systolic blood pressures; BAS, unstimulated conditions; DOB, after
dobutamine stimulation.
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both when assessed in unstimulated and dobutamine-
stimulated conditions (r0.45 and r0.47, respectively;
P  .05 for both). Echocardiography- and angiography-
derivedmeasures of LVEF obtained throughout the treat-
ment period were positively associated (r  0.55, P 
.004). PeakEFof theLV showeda trend toward adecrease
in PWS subjects and was, by the study end, lower than in
controls. Diastolic function, as assessed by the LV peak
filling rate, near-significantly decreased during the study
period (P  .067).
There were no differences in GH therapy-associated
metabolic and cardiovascular outcomes in PWS patients
when stratified by GHD, genetic setting or gender (data
not shown).No relationship betweenGHdose or attained
IGF-I levels and any cardiac variables obtained during the





















Le ventricle mass (indexed by fat mass) 
Figure 1. bivariate correlation analysis calculated on cumulative
longitudinal data collected in 9 adult PWS patients, measured between
free-fat body mass (kg, DXA) and LV mass indexed by fat mass (%,
echocardiography) obtained at baseline (triangles), after 1 year (circles)
























Figure 2. bivariate correlation analysis calculated on cumulative
longitudinal data collected in 9 adult PWS patients, measured between
BMI (kg/m2) and early to late mitral flow velocities (E/A,
echocardiography) obtained at baseline (triangles), after 1 year (circles)










































Dobutamine-smulated le ventricle ejecon fracon (%) 
Figure 3. bivariate correlation analysis calculated on cumulative
longitudinal data collected in 9 adult PWS patients, measured between
free-fat body mass (kg, DXA) and unstimulated (top panel) or
dobutamine-stimulated (lower panel) LV EF (%, radionuclide
angiography) obtained at baseline (triangles), after 1 year (circles) and
after 4 years GH treatment (squares). One fit line is expressed for
whole data set.
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Discussion
Our study in a selected sample of severely obese adults
with PWS found that 4 years treatmentwithGH improved
lean body mass, decreased visceral adiposity and reduced
proinflammatorymarkers associatedwithobesity.During
the course of GH treatment, an increase in LV mass was
observed in PWS patients and all functional variables as-
sessed by echocardiography and radionuclide angiogra-
phy remained within the normal range, despite the evi-
dence of a trend toward a decline of diastolic and systolic
indices of the LV. These results suggest that long-termGH
administration can contribute to stabilize cardiovascular
structure of PWS adults and contrast the inherent negative
outcome associated with the disorder.
Obesity is a hallmark of PWS and a prominent cause of
cardiovascular complications leading to premature mor-
tality. Early dietary treatment is effective in avoiding ex-
cessive gain of bodymass in patientswith PWS, but results
in shorter stature unlessGH treatment is commenced (22).
Althoughmany studies published to date have reported an
overall narrow prevalence of cardiovascular events in
PWS (23–26), this inference is possibly flawed by the pre-
mature mortality affecting PWS, which could mask the
development of cardiovascular accidents later in life. In
such context, obesity-related cardiovascular and respira-
tory diseases are actually a major cause of death, both
during child- and adulthood (27), and the reportedly in-
creased prevalence of diabetes mellitus further enhances
their unfavorable cardiovascular profile (26–30).
The current study used an echocardiographic and scin-
tigraphic methodology to investigate the long-term car-
diovascular outcomeofGHtreatment in adultswith PWS.
Favorable inotropic effects of GH therapy have been con-
sistently described in hypopituitary populations with
GHD, and interventional long-term studies uniformly
stressed the importance of GH replacement to normalize
LVwall thickness, end-diastole volumeand stroke volume
(31). In addition, GH treatment increases LV end-diastole
diameter, and this effect possibly originates from an in-
creased plasma volume (32). A previous retrospective
analysis by Hauffa et al in PWS children documented a
trend for a positive effect of GH therapy on LV end-sys-
tolic diameter, a contractility index, compared to GHD
controls (33). Our analysis in PWS adults identified a pe-
culiar profile of cardiac response during GH therapy,
which consisted of an incremental variation of LV mass
determined by the increase of end-diastole diameter,while
no change in LV cardiac walls thickness could be docu-
mented. Although there were no systolic or diastolic ab-
normalities occurring with GH therapy, the LV EF ap-
peared to decline by the study end. It is worth noting that
the analytical solution provided by echocardiography is
faster and the examination is easily performed in the rou-
tine practice, but its accuracy is possibly affected by the
abnormal body conformation and excessive adiposity of
PWS patients. When a more sensitive functional analysis
was used, eg, radionuclide angiography, again we did not
document diastolic and systolic dysfunctions during the
GH treatment period. However, values of peak systolic
and diastolic function (ie, LV EF and filling rate measured
during dobutamine) averagely decreased during the study,
albeit remaining within the normal range for the whole
study duration.While these contradictory data convey the
impression of a peculiar pattern of cardiac response in
PWS that may not entirely fulfill Laplace’s law, relatively
to the effects of GH (34), it should be borne in mind that
our study included a limited sample and that dobutamine,
herein used as a proxy of the stress test to compensate for
motor disabilities of PWS patients, may not provide a suf-
ficient stimulus in obese PWS subjects to illustrate GH
effects on cardiac function adequately.
To further explain the atypical pattern of response of
PWS adults, as compared to GH-treated hypopituitary
GHD populations (31), a number of phenotypical and
functional characteristics should be considered. First,
there is postmortem evidence in a PWS toddler with sud-
den cardiac death of increased cardiac collagen deposition
and band necrosis (35). In children with PWS, perturba-
tions in the sympathetic nervous system, autonomic dys-
function, as well as inherent low cardiovascular fitness
have been reported (36). Finally, studies in adults with
PWS disclosed the existence of early vascular changes in
the forearm microcirculation (18), decreased chrono-
tropic and inotropic response to -adrenergic stimulus
(19), impaired autonomic regulation (37), increased risk
of sleep apnea as well as abnormal arousal and impaired
cardiorespiratory responses to hypoxia (38). In frail PWS
individuals, these abnormalities can provoke cardiorespi-
ratory failure necessitating treatment by oxygen therapy,
adaptive servoventilation, medications, diet therapy and
rehabilitation (39). Although current data necessarily
warrant confirmation in larger prospective investigations,
we are inclined to consider GH treatment as a valid sup-
portive care for long-termcardiovascular stability in PWS,
which is chronically linked to increased cardiovascular
risk.
In addition to the previous, positive changes of other
systemic correlates could develop with GH therapy and,
hence, beneficially act on the cardiovascular outcome of
PWS patients. Improvements of body composition have
longbeen recorded inPWSchildren treatedwithGHtreat-
ment, which has been thus proposed to delay the onset of
obesity into adolescence (40–43). In long-term investiga-
doi: 10.1210/jc.2015-1063 jcem.endojournals.org 7
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 13 March 2015. at 01:09 For personal use only. No other uses without permission. . All rights reserved.
tions in PWS children, GH treatment for up to 6 years
improved fat mass, motor development and muscle
strength (10, 44). In adults with the disease, GH therapy
for up to 2 years decreased abdominal fat content and
increased muscle fat content, muscle mass and functions
(14, 15, 43, 45, 46), and advantaged the sustainable phys-
icalworkload (47).Our results confirm the benefits ofGH
therapy on body composition and visceral fat and, like
other long-term studies (11), suggest that GH effects oc-
curred as early as after 1 year of therapy, and remained
stable thereafter. GH-dependent improvements in body
composition could benefit exercise capacity and help to
contrast obesity, as well as influence the function of car-
diac parameters, as implied by the associations found in
our analysis between LV parameters and fat free mass or
BMI. Because insulin resistance increased during the
study, there is still a need for serial evaluations of meta-
bolic homeostasis during GH therapy. In addition, the
potential effect of gonadal steroid replacement on our
findings remains to be elucidated.
In conclusion, current data suggest that long-term GH
administration can favor preservation of cardiac andmet-
abolic parameters in adult PWS patients. In association
with strategies for controlling body mass, GH treatment
can be seen as a critical upholder of physiological homeo-
stasis, and could create extended benefits for cardiovas-
cular health in adults with the disease. Cautiously, non-
significant modifications of functional parameters point
out a need for appropriate cardiac monitoring during
long-term management of Prader-Willi Syndrome.
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